Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

Plain-language summary

This study examines a treatment program using various chemotherapy drugs in patients newly diagnosed with acute lymphoblastic leukemia (ALL). It enrolled children aged 1 to 18 diagnosed with non-B-cell ALL by immunophenotyping. The research was conducted in Phase 3 and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Phase 3

Status

Completed

Sponsor

St. Jude Children's Research Hospital

Intervention

Prednisone, Dexamethasone, Vincristine, Daunorubicin, Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase, Methotrexate, Cyclophosphamide, Cytarabine, Etoposide, Mercaptopurine, Imatinib, chemotherapy, intrathecal chemotherapy, steroid therapy, hematopoietic stem cell transplantation

Start date

7/8/2000

Estimated completion

4/1/2014

Countries

United States

Related genes

Locations

• Memphis, United States
• Fort Worth, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Diagnosis of non-B-cell ALL by immunophenotyping, as determined by the reactivity pattern to a panel of monoclonal antibodies with flow cytometry as well as morphology and cytochemical staining.
* Age range: 1 to 18 years (inclusive).

Exclusion Criteria:

• Previously treated with chemotherapy for one week or longer.